Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
23 May 2024
|
|
N 14:51 | Glofitamab-gxbm 2 changes history +8,803 [Muhammad Waleed (2×)] | |||
|
|
14:51 (cur | prev) +6,189 Muhammad Waleed talk contribs | ||||
| N |
|
14:40 (cur | prev) +2,614 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft...") | |||
|
|
N 14:22 | Rozanolixizumab-noli 2 changes history +8,759 [Muhammad Waleed (2×)] | |||
|
|
14:22 (cur | prev) +5,524 Muhammad Waleed talk contribs | ||||
| N |
|
12:43 (cur | prev) +3,235 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac...") | |||
|
|
m 07:03 | Non-degenerate nucleotides per response element 2 changes history −98 [Marshallsumter (2×)] | |||
| m |
|
07:03 (cur | prev) −49 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:01 (cur | prev) −49 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
04:38 | Pegunigalsidase alfa-iwxj 4 changes history +3,608 [Alen Antony (4×)] | |||
|
|
04:38 (cur | prev) +1,255 Alen Antony talk contribs | ||||
|
|
02:34 (cur | prev) +83 Alen Antony talk contribs | ||||
|
|
02:32 (cur | prev) +931 Alen Antony talk contribs | ||||
|
|
02:18 (cur | prev) +1,339 Alen Antony talk contribs | ||||
|
|
02:01 | Template:KDRG 2 changes history +15 [Kosar Doraghi (2×)] | |||
|
|
02:01 (cur | prev) +18 Kosar Doraghi talk contribs | ||||
|
|
02:00 (cur | prev) −3 Kosar Doraghi talk contribs | ||||
| N 02:00 | Aprocitentan diffhist +16,419 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar.Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=aprocitentan |aOrAn=an |drugClass=endothelin receptor antagonist |indicationType=treatment |indication=hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs |hasBlackBoxWarning=Yes |adverseReactions=edema/fluid retention and anemia |blackBoxWarningTitle=W...") | ||||
|
|
01:49 | (Upload log) [Kosar Doraghi (3×)] | |||
|
|
01:49 Kosar Doraghi talk contribs uploaded File:IMG 1225.jpeg | ||||
|
|
01:28 Kosar Doraghi talk contribs uploaded File:IMG 1224.jpeg | ||||
|
|
01:28 Kosar Doraghi talk contribs uploaded File:IMG 1223.jpeg | ||||
| 00:06 | Sandbox diffhist +9 Alberto Castro Molina talk contribs | ||||
22 May 2024
| 23:54 | Sandbox diffhist −30,274 Alberto Castro Molina talk contribs (Replaced content with " File:Captura de Pantalla 2024-05-18 a la(s) 9.33.11 p.m..png") | ||||
_9.33.11_p.m..png){kind=link}
| 23:53 | Upload log Alberto Castro Molina talk contribs uploaded File:Captura de Pantalla 2024-05-18 a la(s) 9.33.11 p.m..png | ||||
|
|
m 21:33 | Non-degenerate nucleotides per response element 2 changes history +1 [Marshallsumter (2×)] | |||
| m |
|
21:33 (cur | prev) 0 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
04:17 (cur | prev) +1 Marshallsumter talk contribs (→Averages per Orders) | |||
|
|
04:26 | Pegunigalsidase alfa-iwxj 3 changes history +1,266 [Alen Antony (3×)] | |||
|
|
04:26 (cur | prev) +459 Alen Antony talk contribs | ||||
|
|
04:06 (cur | prev) +752 Alen Antony talk contribs | ||||
|
|
03:57 (cur | prev) +55 Alen Antony talk contribs | ||||
| 04:02 | FUTIBATINIB diffhist +3,715 Hafiza Amna Qadeer talk contribs | ||||
21 May 2024
|
|
m 22:47 | Non-degenerate nucleotides per response element 3 changes history −152 [Marshallsumter (3×)] | |||
| m |
|
22:47 (cur | prev) −45 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
20:11 (cur | prev) −50 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
18:25 (cur | prev) −57 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
N 22:01 | Vonoprazan, amoxicillin, and clarithromycin 2 changes history +8,611 [Rithish Nimmagadda (2×)] | |||
|
|
22:01 (cur | prev) +1,587 Rithish Nimmagadda talk contribs | ||||
| N |
|
18:33 (cur | prev) +7,024 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=vonoprazan, amoxicillin, and clarithromycin |aOrAn=a |drugClass=Potassium-competitive acid blocker |indicationType=treatment |indication=- erosive esophagitis (all grades) and relief of heartburn associated with erosive esophagitis in adults. ,Helicobacter pylori Infection |adverseReactions=-Common adverse reactions (≥2%) with vonoprazan when used for healing of erosive esophagitis: gastritis, diarrhea, abdom...") | |||
| N 21:25 | Pegunigalsidase alfa-iwxj diffhist +824 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=pegunigalsidase alfa-iwxj |indicationType=treatment |indication=Fabry's disease in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis. |blackBoxWarningTitle=HYPERSENSITIVITY REACTIONS including Anaphylaxis |blackBoxWarningBody=Patients may experience hypersensitivity reaction including a...") | ||||
| N 16:59 | Pirtobrutinib diffhist +4,566 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=pirtobrutinib |aOrAn=an |drugClass=noncovalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). |indicationType=treatment |indication=elapsed or refractory MCL in adults who have received at least 2 lines of prior systemic therapy, including a BTK inhibitor; designated an orphan drug by FDA for treatment of MCL and also in treatment of CLL or SLL in adults who have received at least 2 prior lines of th...") | ||||
|
|
N 00:12 | Elacestrant 2 changes history +3,173 [Rithish Nimmagadda (2×)] | |||
|
|
00:12 (cur | prev) +313 Rithish Nimmagadda talk contribs | ||||
| N |
|
00:09 (cur | prev) +2,860 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=elacestrant |aOrAn=an |drugClass=estrogen receptor antagonist |indicationType=treatment |indication=estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer that has progressed following ≥1 line of endocrine-based therapy in postmenopausal women or adult men. |fdaLIADAdult=Dosage of elacestrant hydro...") | |||
20 May 2024
|
|
23:07 | User:Rithish Nimmagadda 3 changes history +62 [Rithish Nimmagadda (3×)] | |||
|
|
23:07 (cur | prev) +25 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
20:32 (cur | prev) +23 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
20:18 (cur | prev) +14 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 23:07 | Velmanase alfa-tycv diffhist +7,709 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=velmanase alfa-tycv |aOrAn=an |drugClass=recombinant preparation of human lysosomal alpha-mannosidase |indicationType=treatment |indication=non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients |adverseReactions=Most common adverse reactions (incidence >20%) are hypersensitivity reactions (including anaphylaxis), nasopharyngitis, pyrexia, headache, and arthralgia. |blac...") | ||||
|
|
N 20:36 | Retifanlimab-dlwr 3 changes history +8,754 [Rithish Nimmagadda (3×)] | |||
|
|
20:36 (cur | prev) −296 Rithish Nimmagadda talk contribs | ||||
|
|
20:33 (cur | prev) +86 Rithish Nimmagadda talk contribs | ||||
| N |
|
20:31 (cur | prev) +8,964 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=retifanlimab-dlwr |aOrAn=an |indicationType=treatment |indication=adults with metastatic or recurrent locally advanced Merkel cell carcinoma . Indication approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. |adverseReactions=Adverse effects (≥10%): fatigue...") | |||
| N 20:18 | Tofersen diffhist +3,936 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=tofersen |aOrAn=an |drugClass=antisense oligonucleotide |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |adverseReactions=he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia. |fdaLIADAdult=...") | ||||
| m 19:55 | Non-degenerate nucleotides per response element diffhist −51 Marshallsumter talk contribs (→Tabulation of counts) | ||||
|
|
03:56 | Leniolisib 2 changes history +3,116 [Alen Antony (2×)] | |||
|
|
03:56 (cur | prev) +1,712 Alen Antony talk contribs | ||||
|
|
03:38 (cur | prev) +1,404 Alen Antony talk contribs | ||||